An interventional study of Luo-Fu-Shan Plaster and The placebo 10g in Arthritis, Rheumatoid, sponsored by Guang'anmen Hospital of China Academy of Chinese Medical Sciences. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-05-13.
Sponsored by Guang'anmen Hospital of China Academy of Chinese Medical Sciences · Not applicable, Interventional, and Treatment
The aim of this study is to assess the efficacy and safety of Luo-Fu-Shan Plaster in patients with Rheumatoid Arthritis.
The investigators are inspired by Chinese traditonal herb, an therapy for thousands of years, and take its advantage to make Luo-Fu-Shan Plaster in order to get an effective and safe treatment for active RA patients. The study is a multicenter, randomized, double-blind, placebo-controlled trial.
3,554 studies on the registry are indexed under Arthritis; 317 are open to participants now.
This study's planned enrollment of 180 is above the median of 90 across 2,377 interventional studies indexed under Arthritis.
Browse Arthritis studies →Guang'anmen Hospital of China Academy of Chinese Medical Sciences is the lead sponsor of 133 studies on the registry; 36 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
10g，once daily，4 weeks
Drug: Luo-Fu-Shan Plaster
10g，once daily，4 weeks
Drug: The placebo 10g
Luo-Fu-Shan Plaster 10g，once daily，4 weeks
Placebo 10g，once daily，4 weeks
Also known as: placebo
The changes of Visual Analogue Scale(VAS) pain score
The changes of Visual Analogue Scale(VAS) pain score of global health status, the patient's assessment of pain on a visual analogue scale. The score their pain intensity in the most affected joint on a 0-10 cm Visual Analogue Scale Score (VAS), ranging from no pain (0) to extremely pain (10).
Time frame: Day 1 to Week 4
The changes of the Disease Activiyu Score (DAS28)
The changes of the Disease Activity Score (DAS28).The score their pain intensity in the most affected joint on a 0-10 cm Disease Activity Score (DAS28), ranging from no pain (0) to extremely pain (10).
Time frame: Day 1 to Week 4
The score of the Health Assessment Questionnaire (HAQ-DI)
the patient's assessment of function using a modified version of the Health Assessment Questionnaire (HAQ).The score their level, ranging from no difficuties(0),some difficulties(1),a lot of difficuties(2) to coud not finish(3).
Time frame: Day1 to Week 4
The score of the RA-PRO
the patient's assessment of function using a modified version of the RA-PRO which ranging from 0 to 3.
Time frame: Day 1 to Week 4
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Guang'anmen Hospital of China Academy of Chinese Medical Sciences